Related Experiment Video
Updated: May 19, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Comparability of critical quality attributes for establishing biosimilarity
Jason J Z Liao1, Patrick F Darken
1A Plus A Statistical Services, LLC, Lansdale, PA, U.S.A. a4statistics@gmail.com
Statistics in Medicine
|August 21, 2012
Summary
Developing biosimilar products requires demonstrating quality biosimilarity. This study introduces a statistical method using a plausibility interval for head-to-head comparisons, establishing a benchmark for reference product variability.
Area of Science:
- Biopharmaceutical Development
- Statistical Methodology
- Quality Control
Background:
- Developing biosimilar products necessitates rigorous demonstration of quality, safety, and efficacy compared to a reference product.
- Comparability studies are crucial for assessing biosimilarity, requiring direct side-by-side comparisons of quality attributes.
- Current methods for head-to-head quality attribute comparisons may require refinement for robust biosimilarity assessment.
Purpose of the Study:
- To develop and present a novel statistical method for unpaired head-to-head quality attribute comparisons in biosimilar development.
- To establish a benchmark for claiming comparability by utilizing a plausibility interval derived from reference product self-comparison.
- To inform the extent of safety and efficacy data required by robustly demonstrating quality biosimilarity.
Main Methods:
- Development of a statistical method for unpaired head-to-head quality attribute comparisons.
- Implementation of a plausibility interval, using reference product self-comparison data to define acceptable variability.
- Validation of the proposed method through simulation studies and analysis of real-world data sets.
Main Results:
- The proposed statistical method effectively facilitates head-to-head quality attribute comparisons.
- The plausibility interval provides a robust goalpost for claiming comparability by accounting for inherent reference product variability.
- Simulations and real data analyses demonstrate the method's performance in assessing biosimilarity.
Conclusions:
- The developed statistical method offers a reliable approach for demonstrating quality biosimilarity in biosimilar product development.
- Utilizing a reference product self-comparison-derived plausibility interval enhances the rigor of comparability studies.
- This stepwise approach aids in efficiently determining the necessary scope of clinical and non-clinical studies for biosimilar approval.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:14Drug Dissolution: Requirements and Profile Comparison
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...